Aspen sinks to four-month low as volumes surge after Glaxo sells

accreditation
Share your Subscriber Article
You have 5 articles to share every month. Send this story to a friend!
iStock

Johannesburg - Aspen Pharmacare Holdings [JSE:APN] shares slumped to the lowest in more than four months and trading volumes surged after the UK’s GlaxoSmithKline said it has disposed of the final portion of its stake in Africa’s largest generic drug maker.

The stock fell as much as 3.8% to R304.74, the cheapest since May 20, and traded 2.7% lower at R308.25 as of 10:15 in Johannesburg. More than 5.9 million shares were traded; equivalent to almost five times the three-month daily average.

Glaxo sold 28.2 million shares, equal to 6.2% of Aspen’s ordinary share capital, to institutional investors for 300 rand each or R8.47bn according to a statement on Thursday.

Support independent journalism
Subscribe to News24 for just R75 per month to read all our investigative and in-depth journalism.
Subscribe
Already a subscriber? Sign in
Rand - Dollar
14.28
-0.4%
Rand - Pound
19.92
-0.3%
Rand - Euro
17.03
-0.4%
Rand - Aus dollar
10.81
-0.3%
Rand - Yen
0.13
-0.4%
Gold
1,777.78
-0.0%
Silver
25.96
+0.3%
Palladium
2,621.25
+0.2%
Platinum
1,084.00
-0.7%
Brent Crude
75.19
+0.5%
Top 40
59,882
+0.2%
All Share
65,935
+0.2%
Resource 10
63,108
+0.2%
Industrial 25
86,902
+0.1%
Financial 15
12,941
+0.4%
All JSE data delayed by at least 15 minutes Iress logo
Company Snapshot
Voting Booth
Should government have assigned a majority shareholding in SAA to the private sector?
Please select an option Oops! Something went wrong, please try again later.
Results
Yes, It's a good decision
70% - 589 votes
Not a good move
9% - 72 votes
Too early to tell
22% - 184 votes
Vote